Tenax Therapeutics Q1 net loss widens to $3.8M; Phase 3 LEVEL study enrolling

TENAX THERAPEUTICS, INC.

2025-Q1 EPS reported -$3.12

Net loss of $3.8M vs $1.4M in Q1 2023; R&D expenses rose to $2.7M from $0.3M.
Cash $12.5M; raised ~$8.0M net in Feb 2024 public offering.
Phase 3 LEVEL study for PH-HFpEF enrolling; 24 sites initiated, 152 patients planned.
Secured global development/commercial rights to levosimendan in PH-HFpEF; new patent issued (US 11,969,424).
Topline data from LEVEL expected second half 2025.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

TENAX THERAPEUTICS, INC. reported first quarter ended March 31, 2024 results: net income $3.8 million.

Period: first quarter ended March 31, 2024
Net income: $3.8 million
Result: reported results

Exact text from the filing

Tenax Therapeutics reported a net loss for the first quarter of 2024 of $3.8 million

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

TENAX THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001654954-24-006131

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.